Amleto D’Agostino, Fondazione SDN, 25 Ottobre 2013...Mario De Rosa (SUN) Chiara Schiraldi (SUN)...

Amleto D’Agostino, Fondazione SDN, 25 Ottobre 2013

High quality offerin terms of

facilities and tools (technology

platforms)

Extraordinary offerin terms of

knowledge and research

capabilities

Feeble bio-industrial

development

Key issues for Campania Bio-community

Strong science base centres with

a high skilledworkforce

CAMPANIA BIOSCIENCE: NETWORK IN PROGRESS

CAMPANIA BIOSCIENCE: NETWORK IN PROGRESS

Scientific Offer

Extraordinary offer in terms of biology sciences-oriented research institutes/centres

4 Universities

5 National Research Council Institutes and “Anton Dohrn” Zoological Institute of

Naples

3 Biotechnology research networks: BioTekNet; DFM; GEAR

3 No profit bio-consortiums for research: CEINGE, TIGEM and BIOGEM

30.000 square meters of laboratories

60 patents

"BIO" AREA - EMPLOYEES IN R&D IN "CONVERGENCE" REGIONS

Source: Cineca data (on February 2011) and National Research Council (CNR)

HEALTH AND BIOTECH - BENCHMARK EMPLOYEES IN R&D

Source: Cineca data (on February 2011) and National Research Council (CNR)

HEALTH AND BIOTECH - SCIENTIFIC PUBLICATIONS

0 10 20 30 40 50 60Numero scienziati presenti nella Top Italian Scientists

Region

i ana

lizzate

 Campania

Sicilia

 Puglia

 Calabria

Source: Cineca data (on February 2011) and National Research Council (CNR)

NUMBER OF BIOTECH COMPANY, TURNOVER, INVESTMENTS IN R&D AND R&D EMPLOYEES

COMPANIES IN CAMPANIA BIO-COMMUNITY

Campania Region currently hosts pretty remarkable bio-companiessuch as HARDIS belonging to KEDRION group; ALTERGONITALIA (linked to the Swiss company IBSA); OKAIROS;NOVARTIS; DSM and the newborn company ARTERRABIOSCIENCE. In spite of its outstanding industrial growth forsouthern Italy, the number of the industrial companies is far behindthe strong presence of high level research centers andcompetences

MAIN COMPETENCES

Gene expression and proteomics

Bioinformatics

Pharmacogenomics

Industrial Biotechnologies

Nutraceuticals, cosmeceuticals and functional foods

Bioremediation and biodegradation

Molecular diagnostics

Gene therapy

MAIN CHALLENGES

To finalize financial efforts by a medium-long-term strategic approach

To improve results and Intellectual Property exploitation

To enhance technology transfer

To support transnational researches and projects

FIRST CLUSTERING STEP: THE IMPLEMENTATION OF REGIONAL NETWORK

Centro Regionale di Competenza

in Biotecnologie Industriali

Beginning 2008

14.12.2007

14.12.2007

SECOND CLUSTERING STEP: THE IMPLEMENTATION OF A CLUSTER

Nutraceutis and Food

Industries

Diagnostic Industries

Pharma Industries

STATE OF THE ART

22/03/2011• Presentazione studio di fattibilità

23/04/2012

• Approvazione dello studio di fattibilitàCampania Bioscience da parte del MIUR

07/08/2012

• Stipula Accordo di Programma QuadroMIUR – Regione Campania

Next step (November 2013): Evaluation of the executive project

Feasibility Study presentation to build theCluster Campania Bioscience

Feasibility Study of Campania Bioscience approval by theItalian Ministry for Universities and Research

Conclusion of Framework Programme Agreement MIUR-Campania Region

14/02/2013• Establishment of Campania Bioscience SCaRL ( Ltd.

Company)

Legal name Campania Bioscience SCaRL

Legal status Società Consortile a Responsabilità Limitata

MembersResearch organizationsCompaniesScientific Parks

Shares44 % Research organizations44 % Companies12 % Scientific Parks

Object No-profit

Capital 1,7 Millions Euros

LEGAL ENTITY OF THE CLUSTER

CAMPANIA BIOSCIENCE’S Shareholders

N. 8 Research organizations

48 companies:13 big enterprises11 medium enterprises24 small enterprises

THE INDUSTRIAL SHAREHOLDERS

THE INDUSTRIAL SHAREHOLDERS

THE INDUSTRIAL SHAREHOLDERS

UNIVERSITIES, RESEARCH ORGANIZATIONS AND SCIENTIFIC PARKS

GOVERNANCE OF CAMPANIA BIOSCIENCE

Researchorganizations

Companies TT Structures

3 3 1

Board od Directors

Shareholders’ Assembly

Chairman

General Manager

Audit Committee

GTT 4

Diagnostic and 

Biomedical

GTT 3

Nutraceutical

and 

Cosmeceutical

GTT 5

New Therapies

GTT 1Technology transfer, 

Networking. Dissemination

GTT 2Training and 

development of  human 

resources

Confindustria

1

Board of management

GTT M Monitoringexecutive projects

GTT MFranco Salvatore (Ceinge)GiovannangeloOriani (Ceinge)Francesco Rossi (SUN)Mario De Rosa (SUN)Chiara Schiraldi(SUN)Paolo Netti (FII)Tommaso Russo (FII)Vincenzo Pavone (FII)Francesco Beguinot (FII)Fabrizio Ferrando (Esaote)

GTT 1 Roberto Vona(FII)Mario Sorrentino (SUN)Alessandro Indiveri(Technapoli)Pino Manco (CNR)Roberto Tagliaferri(Unisa)Alfonsina Migliozzi(Mataluni)Stefania Spinelli (PST SA)Andrea Di Maso (Biogem)Gianluca Di Brina (Engineering) Concetta D’Orio (BioTekNet)

GTT 2 Vincenzo Maggioni (SUN) Roberto Parente (Unisa) Giuseppe Zollo (FII) Giovanni De Simone (FII)Maria Rosaria Napolitano (Unisannio)Gabriella Minchiotti (CNR)Domenico Gambacorta (Biogem)Paola Mazzocca(TechnapolI)Isabella Colamarco (PST SA)Achille Masturzo(BioTekNet)

GTT 3 Gabriele Riccardi (FII)Ettore Novellino (FII)Chiara SchiraldiElena De Marco (Mataluni)Agostino CasapulloBarbara Nicolaus (CNR) Luigi Fontana (UNISA) Pasquale Vito (Unisannio)Salvatore Riccio (UNISA) Andrea Giori(IBSA)

GTT 4Alberto Luini (CNR)Alessandro Nencioni(Esaote)Giuseppe Castaldo (FII)Marco Salvatore (FII)Lucia Altucci (SUN)Vincenzo Nigro(SUN)Raffaele Riccio (UNISA) Francesco Mancini (Unisannio)Mario De Felice (FII) Massimiliano Minale (Damor)

GTT 5Fortunato Ciardiello (SUN)Stefania Amorosi (Altergon)Gianfranco Di Renzo (FII)Lucio Pastore (FII)Liberato Berrino(SUN)Aldo Pinto (UNISA)Vittorio de Franciscis (CNR) Claudio Pisano (Biogem)Francesco Izzo (Pascale) Anna Tortiglione (Damor)

LINE 1 – R&D ACTIVITIES OF THE CLUSTER

Line 1 – Infrastructures and Industrial Research

Enforce and integrate the R&D infrastructures(companies and research organizations) andimplement industrial research activities in thefollowing three thematic areas:

1) Development and Production of nutraceuticals andcosmeceuticals

2) Diagnostics, biosensors and innovativetechnologies for biomedical industry

3) New therapies

CAMPANIA BIOSCIENCE: R&D PROJECTS

1. Strategies for the recovery of bioactive compounds from waste in the foodindustry

2. Design, development and production of functional foods and / or enriched

3. Development and testing of molecules with nutraceutical and cosmeceuticalproperties

4. New strategies for medical and molecular diagnosis and for food traceabilityand monitoring

5. New strategies for medical and molecular diagnosis and for food traceabilityand monitoring

6. Smart materials and new devices for biomedical applications

7. Preclinical development of new therapies and innovative strategies for theproduction of molecules with pharmacological activity

8. Preclinical and phase o and 1 clinical evaluation of molecules withnutraceutical, cosmeceutical and pharmaceutical properties and/or newindications for already approved compounds

ECONOMIC OPPORTUNITIES

HEALTH CAGR 2009-2014

EU market 2008 (billions $)

Nutraceuticals 4,3% 60,33

In vitro diagnosticsand imaging

5,3% 16,10

New therapies 10% 132,48

Total 208,91

2008 European data on Health market (including nutraceuticals, diagnostics in vitroand imaging and new therapies) was US$ 208.91 billions. Growth estimation peryear is more than 6% from 2009 to 2014.

LINE 2 AND 3 – TRAINING AND CLUSTER START-UP

Line 2 – Human Resources ValorisationTraining activities of technical profiles in line with theindustrial research projects of the Cluster and otheractivities to attract young talents

Line 3 – Start-up of the Cluster and activities of marketing,internationalisation and technology transferManagement and technology transfer activities supportingnewcos and start-up

PRIORITIES OF HORIZON 2020 AND CLUSTER VISION

Priorities of Horizon 2020: Demografic change, wellbeing, food security

Technology objectives of Campania Bioscience Cluster:

1) Nutraceutical development2) Growth and children products3) Functional food4) Innovative cosmeceuticals5) Food genetic-molecular tracking

Priorities of Horizon 2020: Health, biotechnologyand advanced manifacturing

Technology objective of Campania Bioscience Cluster:

1) New therapies2) Pharma treatment customization3) Systems for molecular and imaging diagnostics4) Biomedical technologies5) Innovative bioprocesse

PRIORITIES OF HORIZON 2020 AND CLUSTER VISION

…….To Europe

Il Cluster campano Salute, Biotecnologie e Agroalimentare

(Contratto di Rete)

Le Bioregioneuropee

Il Cluster tecnologico nazionale delle

Scienze della Vita

AliseiMarea (APP)

M2Q (APP)

Sorriso (APP)

Ehealthnet (APP)

Biocam (APP)

Dr Amleto D’Agostino, General Manager Campania BioscienceTel +390815667678Mail campania.bioscience@legalmail.it